{"nct_id":"NCT01282463","title":"Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma","status":"COMPLETED","status_verified_date":"2019-08","start_date":"2011-04","start_date_type":null,"primary_completion_date":"2015-02","primary_completion_date_type":"ACTUAL","completion_date":"2015-03","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["LLY"]}